Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug-drug interactions.

MLA

Occhipinti, Giovanni, et al. “Switching from Cangrelor to Oral P2Y 12 Inhibitors: A Focused Review on Drug-Drug Interactions.” Expert Opinion on Drug Metabolism & Toxicology, vol. 21, no. 1, Jan. 2025, pp. 29–40. EBSCOhost, https://doi.org/10.1080/17425255.2024.2418033.

APA

Occhipinti, G., Ortega-Paz, L., Franchi, F., Rollini, F., Capodanno, D., Brugaletta, S., & Angiolillo, D. J. (2025). Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug-drug interactions. Expert Opinion on Drug Metabolism & Toxicology, 21(1), 29–40. https://doi.org/10.1080/17425255.2024.2418033

Chicago

Occhipinti, Giovanni, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Davide Capodanno, Salvatore Brugaletta, and Dominick J Angiolillo. 2025. “Switching from Cangrelor to Oral P2Y 12 Inhibitors: A Focused Review on Drug-Drug Interactions.” Expert Opinion on Drug Metabolism & Toxicology 21 (1): 29–40. doi:10.1080/17425255.2024.2418033.